Genia Long

Boston
Education
M.P.P., Harvard University; S.B., Massachusetts Institute of Technology
Summary of Experience
Ms. Long is an expert in the economics and business strategy of innovation and growth. She has assisted executives in pharmaceuticals and biotechnology, consumer packaged goods, and information technology with maximizing the value of their products, services, and innovative technologies by addressing fundamental challenges related to research and development, business planning, opportunity assessment, and competitive market strategy. In health care, Ms. Long’s work has included projects for pharmaceutical and biotech manufacturers; joint ventures in research, teaching, and patient care; academic medical centers; and general and specialty hospitals. For pharmaceutical manufacturers, Ms. Long’s work has encompassed pricing and managed markets strategy, account segmentation, and contracting recommendations for new and established brands; market research studies on branded product demand and launch strategy; pharmacoeconomic analyses of the value and impact of drug therapy; and forecasting and analytical modeling of growth opportunities and business options.
Selected Publishing
-
Continuing trends in U.S. brand-name and generic drug competition
Journal of Medical Economics, 2021
2021Grabowski H, Long G, Mortimer R, Bilginsoy M
-
Federal government-interest patent disclosures for recent top-selling drugs
Journal of Medical Economics, 2019
2019 -
Are Payers Ready to Address the Financial Challenges Associated with Gene Therapy?
Health Affairs, June 28, 2018
2018 -
-
Challenges in Developing and Assessing Comparative Effectiveness Evidence for Medical Technology
Decision Making in a World of Comparative Effectiveness Research
2017Price R, Long G
-
Insurance Switching and Mismatch Between the Costs and Benefits of New Technologies
The American Journal of Managed Care, December 2017
2017 -
Updated trends in US brand-name and generic drug competition
Journal of Medical Economics, 2016 04: 1-9. e-pub ahead of print 2016/04/12
2016Grabowski H, Long G, Mortimer R, Boyo A.
-
Innovation in the Biopharmaceutical Pipeline: A Multidimensional View
Report, January 2013
2013Long G, Works J
-
Recent Average Price Trends for Implantable Medical Devices, 2007-2011
White Paper
2013Long G, Mortimer R, Sanzenbacher G
-
Recently Released FDA Guidance and Biosimilar Development: Implications for the Litigation Environment
FDLI Update, March/April 2012
2012 -
Data Exclusivity for Biologics
Nature Reviews Drug Discovery 10, 15-16 (January 2011) - doi:10.1038/nrd3277
2011 -
Reading of Biosimilar Law Could Mean One Day or Years Until Competitors on Market
Specialty Pharmacy News, February 2011, Volume 8, Number 2
2011 -
President Reignites Biologics Exclusivity Battle With Proposal for Seven Years
Specialty Pharmacy News, March 2011, Volume 8, Number 3
2011 -
Commercial Importation of Prescription Drugs in the United States: Short-Run Implications
Journal of Health Policy, Politics, and Law, April 2011
2011Danzon P, Johnson S, Long G, Furukawa M
-
Evolving Brand-Name and Generic Drug Competition May Warrant a Revision of the Hatch-Waxman Act
Health Affairs, 2011, 30(11), 2157-2166
2011Grabowski HG, Kyle M, Mortimer R, Long G, Kirson N
-
Implementation of the Biosimilar Pathway: Economic and Policy Issues
Seton Hall Law Review, Book 2, 41:2
2011Grabowski HG, Long G, Mortimer R
-
Budget Proposals on Biosimilars, “Pay for Delay” Spark Controversy
AIS's Health Reform Week, February 2011, Volume 2, Number 6
2011 -
Data Exclusivity Periods and Next Generation Improvements to Innovator Biologics: Key Issues
Duke University Department of Economics Working Paper, No. 2009-05
2009Grabowski H, Cockburn I, Long G, Mortimer R
-
Data Exclusivity Periods for Biologics: Updating Prior Analyses and Responding to Critiques
Duke University Department of Economics Working Paper, No. 2008-10
2008 -
The Value Of Antihypertensive Drugs: A Perspective On Medical Innovation
Health Affairs
2007Cutler D, Long G, Berndt E, Royer J, Fournier A, Sasser A, Cremieux P
-
Pharmaceutical Spending and Health Outcomes
Pharmaceutical Innovation: Incentives, Competition, and Cost-Benefit Analysis in International Perspective
2007Cremieux P, Jarvinen D, Long G, Merrigan P
-
Antihypertensive drugs: a perspective on the value of improved blood pressure control in the USA
European Heart Journal Supplements
2007Long G, Cutler D, Berndt E
-
The Effect on Federal Spending of Legislation Creating a Regulatory Framework for Follow-on Biologics: Key Issues and Assumptions
White Paper
2007Grabowski H, Cockburn I, Long G, Mortimer R, Johnson S
-
The Market For Follow-On Biologics: How Will It Evolve?
Health Aff 2006 Sep-Oct;25(5):1291-1301
2006Grabowski H, Cockburn I, Long G
-
The Impact of Antihypertensive Drugs on the Number and Risk of Death, Stroke, and Myocardial Infarction in the United States
National Bureau of Economic Research Working Paper
2006Berndt E, Sasser A, Long G, Cremieux P, Royer J, Fournier AA